Genmab — April 2017

[E_L]

I could imagine Syros would want to
present this at ASCO also

[Mcjean]

It should pop up on CCN soon;-)

[Mcjean]

i wonder how good six-fold is and 5-10 fold increases in NK cell?

[E_L]

Is that new, the Cable Copenhagen Network ?

[Mcjean]

1-0

[royal]

Juve

[Bulder]

Alcyone er opdateret 7/4. Antallet af lokationer er - siden januar - udvidet fra 179 til 209. Ud af de 209 lokationer er 29 "completed". Ud af 12 US-lokationer er 7 "completed". https://www.clinicaltrials.gov/ct2/show/study/NCT02195479?term=daratumumab+and+velcade&rank=1&show_locs=Y#locn

[KWC]

Tak Gento for update..

[bibob]

God morgen.

[transalp]

Go morgen..

[Helge_LarsenPI-redaktør]

God morgen.

[E_L]

With an estimated enrolment of 700 patients for Alcyone, that would only be 3-4 patients per location. Do you think enrolment will stop when 700ish is reached or does each location need to make its minimum?

[Bulder]

Jeg ved ikke hvad det betyder. Det er jo længe siden, at genmab annoncerede at studiet var fuldt rekrutteret. Jeg troede, at de derved havde nået de 700 pts. Men de fleste lokationer rekrutterer stadig på livet løs. Det undrer mig også at de udvider med 30 lokationer uden at samlet antal pts øges.

[DevOp]

Der indsamles interim efficacy results i Alcyone efter ca. 216 PFS events - gad vide, om Janssen har tænkt sig at offentliggøre dem inden endelig indsamling af efficacy data 1.nov.

[Bulder]

Vil det sige, at de ikke behøver mere end ca 216 pts for at studiet er "fuldt" rekrutteret?

[DevOp]

nope, der indsamler de bare interim results

[DevOp]

Gætter på, at completed locations allerede har haft PFS events for alle deltagende patienter - ellers skulle der gå ca 41 måneder inden PFS assessment, og det kan jeg ikke engang få til at passe med start i dec 2014 og "Estimated Primary Completion Date" nov. 2017 - go figure...

[E_L]

https://www.dovepress.com/new-developments-in-the-treatment-of-multiple-myeloma---clinical-utili-peer-reviewed-article-BTT "New developments in the treatment of multiple myeloma – clinical utility of daratumumab"

[E_L]

"Perhaps, frontline daratumumab may obviate the need for autologous stem cell transplant in certain lower-risk groups or facilitate a fixed duration of maintenance therapy...-"

[Bulder]

Ha ha, lige præcis den sætning skulle jeg lige til at kopiere ind.